Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use UBRELVY safely and effectively. See full prescribing information for UBRELVY. UBRELVY ® (ubrogepant) tablets, for oral use Initial U.S. Approval: 2019
Medication labelWhy this: Advisory · dailymed-prescription
UBRELVY is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine.
- generic_name
- ubrogepant
- product_names
- ubrogepant
- ndc
- 0023-6498, 0023-6498-02, 0023-6498-10, 0023-6498-30, 0023-6498-16, 0023-6498-01, 0023-6498-04, 0023-6501, 0023-6501-02, 0023-6501-16, 0023-6501-10, 0023-6501-30, 0023-6501-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en